Search research articles
Contact Us
Filters
Showing results (1-10 of 10) with videos related to
Page
of 1
Sort By:
Israel Journal of Chemistry
|
June 29, 2011
Maitotoxin: An Inspiration for Synthesis
K C Nicolaou, Robert J Aversa
Angewandte Chemie (International Ed. in English)
|
September 4, 2008
The continuing saga of the marine polyether biotoxins
K C Nicolaou, Michael O Frederick, Robert J Aversa
Journal of the American Chemical Society
|
April 27, 2010
Synthesis of the ABCDEFG ring system of maitotoxin
K C Nicolaou, Robert J Aversa, Jian Jin, et al.
Journal of the American Chemical Society
|
December 21, 2010
Synthesis of the C'D'E'F' domain of maitotoxin
K C Nicolaou, Jae Hong Seo, Tsuyoshi Nakamura, et al.
Journal of the American Chemical Society
|
May 17, 2008
Chemical Synthesis of the GHIJKLMNO Ring System of Maitotoxin
K C Nicolaou, Michael O Frederick, Antonio C B Burtoloso, et al.
ACS Medicinal Chemistry Letters
|
January 16, 2015
Structure-Based Drug Design of Novel Potent and Selective Tetrahydropyrazolo[1,5-a]pyrazines as ATR Inhibitors
Paul A Barsanti, Robert J Aversa, Xianming Jin, et al.
Journal of Medicinal Chemistry
|
August 20, 2025
Discovery of Selective and Orally Bioavailable Heterobifunctional Degraders of Cyclin-Dependent Kinase 2
Philip N Collier, Xiaozhang Zheng, Melissa Ford, et al.
ACS Medicinal Chemistry Letters
|
January 16, 2015
Structure-Based Drug Design of Novel, Potent, and Selective Azabenzimidazoles (ABI) as ATR Inhibitors
Paul A Barsanti, Yue Pan, Yipin Lu, et al.
Journal of Medicinal Chemistry
|
May 31, 2017
Design and Discovery of N-(2-Methyl-5'-morpholino-6'-((tetrahydro-2H-pyran-4-yl)oxy)-[3,3'-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide (RAF709): A Potent, Selective, and Efficacious RAF Inhibitor Targeting RAS Mutant Cancers
Gisele A Nishiguchi, Alice Rico, Huw Tanner, et al.
Journal of Medicinal Chemistry
|
May 7, 2019
Design and Discovery of <i>N</i>-(3-(2-(2-Hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide, a Selective, Efficacious, and Well-Tolerated RAF Inhibitor Targeting RAS Mutant Cancers: The Path to the Clinic
Savithri Ramurthy, Benjamin R Taft, Robert J Aversa, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 10) with videos related to
Sort By:
Page
of 1
Israel Journal of Chemistry
|
June 29, 2011
Maitotoxin: An Inspiration for Synthesis
K C Nicolaou, Robert J Aversa
Angewandte Chemie (International Ed. in English)
|
September 4, 2008
The continuing saga of the marine polyether biotoxins
K C Nicolaou, Michael O Frederick, Robert J Aversa
Journal of the American Chemical Society
|
April 27, 2010
Synthesis of the ABCDEFG ring system of maitotoxin
K C Nicolaou, Robert J Aversa, Jian Jin, et al.
Journal of the American Chemical Society
|
December 21, 2010
Synthesis of the C'D'E'F' domain of maitotoxin
K C Nicolaou, Jae Hong Seo, Tsuyoshi Nakamura, et al.
Journal of the American Chemical Society
|
May 17, 2008
Chemical Synthesis of the GHIJKLMNO Ring System of Maitotoxin
K C Nicolaou, Michael O Frederick, Antonio C B Burtoloso, et al.
ACS Medicinal Chemistry Letters
|
January 16, 2015
Structure-Based Drug Design of Novel Potent and Selective Tetrahydropyrazolo[1,5-a]pyrazines as ATR Inhibitors
Paul A Barsanti, Robert J Aversa, Xianming Jin, et al.
Journal of Medicinal Chemistry
|
August 20, 2025
Discovery of Selective and Orally Bioavailable Heterobifunctional Degraders of Cyclin-Dependent Kinase 2
Philip N Collier, Xiaozhang Zheng, Melissa Ford, et al.
ACS Medicinal Chemistry Letters
|
January 16, 2015
Structure-Based Drug Design of Novel, Potent, and Selective Azabenzimidazoles (ABI) as ATR Inhibitors
Paul A Barsanti, Yue Pan, Yipin Lu, et al.
Journal of Medicinal Chemistry
|
May 31, 2017
Design and Discovery of N-(2-Methyl-5'-morpholino-6'-((tetrahydro-2H-pyran-4-yl)oxy)-[3,3'-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide (RAF709): A Potent, Selective, and Efficacious RAF Inhibitor Targeting RAS Mutant Cancers
Gisele A Nishiguchi, Alice Rico, Huw Tanner, et al.
Journal of Medicinal Chemistry
|
May 7, 2019
Design and Discovery of <i>N</i>-(3-(2-(2-Hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide, a Selective, Efficacious, and Well-Tolerated RAF Inhibitor Targeting RAS Mutant Cancers: The Path to the Clinic
Savithri Ramurthy, Benjamin R Taft, Robert J Aversa, et al.
Page
of 1